



**UNITED STATES PATENT AND TRADEMARK OFFICE**

Re: Application of: Keizo SUGASAWA *et al.*  
Serial No.: 10/500,964  
Examiner: Celia C. CHANG  
Art Unit: 1625  
Filed: July 8, 2004  
For: **2 Acylaminothiazole Derivative and Salt Thereof**

**REVOCATION OF POWER OF ATTORNEY WITH NEW POWER OF ATTORNEY  
AND CHANGE OF CORRESPONDENCE ADDRESS**

Mail Stop: Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

January 31, 2008

Sir:

Submitted herewith is a Revocation of Power of Attorney With New Power of Attorney and Change of Correspondence Address. Also submitted herewith is a Statement Under C.F.R. 3.73(b).

No fee is believed due with this submission. If it is determined that any fees are due, the Commissioner is hereby authorized to charge said fees to Deposit Account No. 50-0552.

Respectfully submitted,

DAVIDSON, DAVIDSON & KAPPEL, LLC

By: Richard V. Zanzalari By: Brenda Maro  
Richard V. Zanzalari  
Reg. No. 49,032  
Reg. No. 50,129

Davidson, Davidson & Kappel, LLC  
485 Seventh Avenue, 14<sup>th</sup> Floor  
New York, N.Y. 10018  
(212) 736-1940



<b>REVOCATION OF POWER OF ATTORNEY WITH NEW POWER OF ATTORNEY AND CHANGE OF CORRESPONDENCE ADDRESS</b>	Application Number	10/500,964
	Filing Date	July 8, 2004
	First Named Inventor	Keizo SUGASAWA
	Art Unit	1625
	Examiner Name	Celia C. CHANG
	Attorney Docket Number	401:1013US

I hereby revoke all previous powers of attorney or authorizations of agent given in the above-identified application:

☐ A Power of Attorney is submitted herewith.  
**OR**  
☒ I hereby appoint the practitioners at Customer Number : 23280

☒ Please change the correspondence address for the above-identified application to:

☒ The address associated with Customer Number: 23280


**OR**

<input checked="" type="checkbox"/> Firm or Individual Name	Davidson, Davidson & Kappel, LLC		
Address	485 Seventh Avenue 14 <sup>th</sup> Floor		
City	New York	State NY	ZIP 10018
Country	USA		
Telephone	212-736-1940	Email	ddk@ddkpatent.com

I am the:

☐ Applicant/Inventor.  
☒ Assignee of record of the entire interest. See 37 CFR 3.71.  
*Statement under 37 CFR 3.73(b) is enclosed. (Form PTO/SB/96)*


**SIGNATURE of Applicant or Assignee of Record**

Signature			
Name	Yuji Watanabe		
Date	1/29/08	Telephone	+81-3-3244-3371

NOTE: Signatures of all the inventors or assignees of record of the entire interest or their representative(s) are required. Submit multiple forms if more than one signature is required, see below\*.

☒ \*Total of 1 forms are submitted.

This collection of information is required by 37 CFR 1.38. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 3 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.



**STATEMENT UNDER 37 CFR 3.73(b)**

Applicant/Patent Owner: Sugasawa, et al.

Application No./Patent No.: 10/500,964

Filed/Issue Date: July 8, 2004

Entitled: 2-Acylaminothiazole Derivative or Salt Thereof

Astellas Pharma Inc., a Corporation

(Name of Assignee)

(Type of Assignee, e.g., corporation, partnership, university, government agency, etc.)

states that it is:

1. ☒ the assignee of the entire right, title, and interest; or  
2. ☐ an assignee of less than the entire right, title, and interest

The extent (by percentage) of its ownership interest is \_\_\_\_\_ %  
in the patent application/patent identified above by virtue of either:

A. ☐ An assignment from the inventor(s) of the patent application/patent identified above. The assignment was recorded in the United States Patent and Trademark Office at Reel \_\_\_\_\_, Frame \_\_\_\_\_, or for which a copy thereof is attached.

OR

B. ☒ A chain of title from the inventor(s), of the patent application/patent identified above, to the current assignee as shown below:

1. From: Sugasawa, et al. To: Yamanouchi Pharmaceutical Co., LTD  
The document was recorded in the United States Patent and Trademark Office at Reel 016329, Frame 0981, or for which a copy thereof is attached.

2. From: Yamanouchi Pharmaceutical Co., LTD To: Astellas Pharma Inc.  
The document was recorded in the United States Patent and Trademark Office at Reel 016784, Frame 0361, or for which a copy thereof is attached.

3. From: \_\_\_\_\_ To: \_\_\_\_\_  
The document was recorded in the United States Patent and Trademark Office at Reel \_\_\_\_\_, Frame \_\_\_\_\_, or for which a copy thereof is attached.

☐ Additional documents in the chain of title are listed on a supplemental sheet.

☐ Copies of assignments or other documents in the chain of title are attached.

**(NOTE:** A separate copy (i.e., a true copy of the original document(s)) must be submitted to Assignment Division in accordance with 37 CFR Part 3, if the assignment is to be recorded in the records of the USPTO. See MPEP 302.08)

The undersigned (whose title is supplied below) is authorized to act on behalf of the assignee:

  
Signature

Yuji Watanabe

Printed or Typed Name

Vice President

Intellectual Property

Title

1/31/08

Date

81-3-3244-3371

Telephone Number

This collection of information is required by 37 CFR 3.73(b). The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.